… of proinflammatory cytokines, immunomodulatory and immunotherapeutic options to
ameliorate cytokine storm and inflammatory responses in patients affected with COVID-19. …

… Immunotherapy is one of … pathogenesis of IRAEs, with attention to gastrointestinal
manifestations, since these are common and potentially dangerous complications of immunotherapy …

… an overview of the current state of molecular pathogenesis and treatment options for HCC. …
immunotherapy in later lines of therapy (>second line). Therefore, the identification of patients…

… mutations, cancer pathogenesis greatly varies depending on … treatment options available
for that particular type of cancer. … cancer immunotherapies tailored to each individual patient. …

… presents at a later age, the majority of patients is not eligible for this highly intensive therapy
… treatment option. Supportive care is particularly applicable for low-risk MDS patients and …

… the immune system, immunotherapy can result in longer … in our understanding of the
pathogenesis of CTCL have led to … describes the current immunotherapeutic options for treatment …

… of the complex AD pathogenesis, is imperative to the successful development of these
disease-modifying agents. This paper will review the active immunotherapies currently in …

… and pathogenesis during the past two decades, have resulted in immunotherapeutic …
with TB, these studies suggest that IL-2 receptor targeting might be a viable treatment option …

… are available, either as monotherapy or in combination with different agents, including
immunotherapies. Here we discuss the available options and how are they continuously evolving. …

… Patients with advanced CTCL manifest immune dysfunction that predisposes to infection …
in the care of patients with CTCL. Recent research has better defined the pathogenesis of these …